-
Hong Kong arrests two for allegedly selling 'seditious' material
-
Laporte wary of Uruguay will to avoid World Cup exit against Spain
-
US promises to protect Gulf states' interests in Iran talks
-
Major Nigeria police reform edges forward with senate approval
-
Trials of two Ebola treatments to start in DRC next week: WHO
-
Trump consolidates rightward shift in Latin America
-
Judge asks why Kennedy Center covering facade after Trump's name removed
-
Olympics to offer all Games competitors $10,000 grants
-
Germany sinks troubled warship project in blow to naval ambitions
-
Left-wing candidate concedes tight Colombia election
-
US health deals cause trouble for Kenya govt
-
Stocks rebound after tech rout, Brent falls below $75
-
Socialism with a twist or crony capitalism? Cuban reforms spark debate
-
Berlin unveils monument to Jehovah's Witnesses murdered by Nazis
-
'Inhumane': Gaza flotilla activists recount Israeli detention ordeal
-
'Fingerprints' of black hole's event horizon detected for first time
-
Spurs sign Dubravka as goalkeeper cover
-
Verstappen seeking home boost with Red Bull upgrades
-
Stocks steady after tech rout, Brent falls below $75
-
'You have to work': Riders brave Rome heat for survival
-
England captain Stokes 'man enough' to apologise for curfew breach
-
France detects first Ebola case outside Africa in current outbreak
-
England captain Stokes 'man enough' to apologise after curfew breach
-
'GTA VI' preorders mark first test for biggest game of 2026
-
German naval ambitions suffer setback as warship order axed
-
Stocks rebound after tech rout, oil prices drop
-
London police to extend use of live facial recognition, drones
-
Australia spy chief warns of Iran terror threat
-
Europe swelters under record-breaking heatwave
-
Heatwave-hit Europe must adapt healthcare: WHO
-
Iran says deal to end Mideast war 'declaration of US defeat'
-
Euclid telescope snaps best photo yet of Milky Way's heart
-
S.Korea chip giant SK hynix seeks $29 bn in Nasdaq listing: regulatory filing
-
French-German tank maker KNDS fires starting gun on mega-IPO
-
'Pragmatists' vs 'hardliners': Is Iran split over US deal?
-
Right-winger Fujimori poised to win Peru president runoff
-
H5 bird flu detected in second Australia state
-
Major power outage in France as Europe wilts under record heat
-
Brazil aim for last 32 as World Cup goes into hectic phase
-
Back in stork: returning birds bring joy to Croatian village
-
Necessity drives gold miners in DR Congo's Ebola epicentre
-
China premier urges AI governance to avoid 'losing control'
-
Japan PM heckled at WWII memorial
-
Colombia beat DR Congo 1-0 to reach World Cup knockouts
-
Hanoi residents mount silent protest over home demolitions
-
West Indies brace for Sri Lanka challenge as Da Silva returns
-
US Congress passes symbolic Iran war rebuke to Trump
-
Stokes urged to use curfew controversy as fuel to beat New Zealand
-
Bolivia's government is 'stoking a civil war,' ex-president Evo Morales tells AFP
-
Seoul bounces as Asian markets look to recover from rout
Bayer says legal woes could force it to pull weedkiller
German chemicals giant Bayer said Friday it could be forced to pull its Roundup weedkiller from the market if it is not able to limit simmering legal troubles.
"We're nearing a point where the litigation industry could force us to even stop selling this vital product," CEO Bill Anderson said at Bayer's annual general meeting.
The Leverkusen-based group has said that after rumbling on for years, it has the aim of "significantly containing litigation by the end of 2026".
"The status quo is not an option," said Anderson, while the stakes for the chemicals and pharmaceuticals producer were "really high".
Bayer has been dogged by lawsuits linked to Roundup since it acquired the US manufacturer Monsanto in a blockbuster deal in 2018.
Claimants have alleged that glyphosate, the active ingredient in Roundup, causes blood cancers but Bayer says scientific studies and regulatory approvals show that the weedkiller is safe.
Bayer has battled to draw a line under Roundup litigation, spending more than $10 billion (8.8 billion euros) to date to settle suits alleging that Bayer failed to disclose health risks.
Earlier this month, Bayer said it would launch another appeal to the US Supreme Court to rule on the Roundup case, its third such attempt.
After being twice rebuffed by the court, Bayer is hopeful of more success following rulings by federal appellate courts, which the German group said support its case.
The renewed request for the Supreme Court to intervene is the first since Anderson took the reins at the chemicals group in 2023.
But Anderson's late arrival has not insulated the American manager from the criticism of shareholders, who voiced their impatience at the meeting.
Bayer has asked investors to approve a capital increase through the issuance of new stock to cover potential legal costs related to Roundup.
Shareholders were being asked to "pay the price" for Roundup's issues, Deka Investment manager Ingo Speich said, describing the move as a "bitter pill to swallow".
"Why should everything be different this time and the wave of lawsuits stopped with more money?", Janne Werning of Union Investment said.
C.Kreuzer--VB